Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
456 Leser
Artikel bewerten:
(2)

Megola, Inc.: Megola Completes Successful Acute Skin Irritation Testing of its Patent-Pending Odor Control SAP for Baby Diapers, Adult Incontinence and Feminine Hygiene Products

Finanznachrichten News

RESULTS showed no signs of skin irritation or defects, no erythema, no edema was present at any time during the study. The primary irritation index of 0.0 out of a possible 8.0 on the pre-treated test substance Diaper Swatches

BONITA SPRINGS, FL / ACCESSWIRE / May 16, 2023 / (OTC PINK:MGON) Megola, Inc. ("MGON", "Company") a Consortium Group of Health Technologies and Eco-Friendly Product Lines announced the successful completion of Acute Skin Irritation Testing of its Patent-Pending Odor Control Superabsorbent Polymers (SAP) for Baby Diapers, Adult Incontinence and Feminine Hygiene Products. The objective of testing was to determine skin irritation by method of EPA OCSPP 870.2500. All procedures followed animal welfare act regulations.

"The material has shown no irritation in the standard protocol for acute skin irritation used for FDA submissions on medical devices. We plan to follow this up with a 50-person acute irritation study and we'll move on to a 100 subject sensitization study in humans," states CEO Robert Gardiner. "We are in active discussions with manufacturing and distribution partners," continues Gardiner.

Superabsorbent polymers (SAP) are used annually in diapers and pads of all types, in a global industry with an annual turnover of more than $100 billion.

ABOUT MEGOLA

Megola Inc is a Nevada Corporation with its Corporate office located in Bonita Springs, FL and traded under the symbol MGON on the OTC Market. Megola is a Consortium Group of Health Technologies and Eco Friendly Product Lines. Megola through product and technology acquisitions has grown to have its own E-commerce Branding Division, Service Department, Licensing Division, Franchise Division all maintaining Megola's diverse manufactured product portfolios which allows the company to integrate into several vertical sales markets worldwide.

LATEST NEWS: https://www.otcmarkets.com/stock/MGON/news

Megola, Inc.
John MacLeod
http://megolacorp.com
http://twitter.com/alo_gem
megola2020@gmail.com
1 888-587-1698

Stock information here: https://www.otcmarkets.com/stock/MGON/overview.

Forward-Looking Statements
The statements contained in this release that are not historical facts are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "could," "should," "expect," "plan," "project," "intend," "anticipate," "believe," "estimate," "predict," "potential," "pursuant," "target," "continue," and similar expressions are intended to identify such forward-looking statements. The statements in this press release that are not historical statements, including statements regarding MGON's plans, objectives, future opportunities for MGON's services, future financial performance and operating results and any other statements regarding MGON's future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts, are forward-looking statements within the meaning of the federal securities laws. These statements are not guarantees of future performance and are subject to numerous risks, uncertainties, and assumptions, many of which are beyond MGON's control, and which could cause actual results to differ materially from the results expressed or implied by the statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict, and include, without limitation, results of litigation, settlements and investigations; actions by third parties, including governmental agencies; volatility in customer spending; global economic conditions; ability to hire and retain personnel; loss of, or reduction in business, with key customers; difficulty with growth and integration of acquisitions; product liability; cybersecurity risk; and, anti-takeover measures in our charter documents. Any forward-looking statement is made only as of the date of which such statement is made. Except as otherwise required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

SOURCE: Megola, Inc.

View source version on accesswire.com:
https://www.accesswire.com/755213/Megola-Completes-Successful-Acute-Skin-Irritation-Testing-of-its-Patent-Pending-Odor-Control-SAP-for-Baby-Diapers-Adult-Incontinence-and-Feminine-Hygiene-Products

© 2023 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.